Dialysis-related amyloidosis

Nephrology Dialysis Transplantation

Volumn 13, Issue SUPPL. 1, 1998, Pages 58-64

  Drücke, Tilman B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Amyloidosis; Beta 2 microglobulin ( 2M); Clinical aspects; Diagnosis; Dialysis; Pathogenesis; Renal failure

Indexed keywords

AMYLOID BETA PROTEIN; BETA 2 MICROGLOBULIN;

CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

AMYLOIDOSIS; BETA 2-MICROGLOBULIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY;

EID: 0031984870     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.suppl_1.58     Document Type: Conference Paper

References (86)

1. Bardin T, Zingraff J, Kuntz D, Drücke T. Dialysis related amyloidosis. Nephrol Dial Transplant 1986; 1: 151-154
2. van Ypersele de Strihou C, Honhon B, Vandenbroucke JM, Huaux JP, Noël H, Maldague B. Dialysis amyloidosis. Adv Nephrol 1988; 17: 401-420
3. Zingrarff J. Noël LH, Bardin T, et al. Beta-2-microglobulin amyloidosis in chronic renal failure (letter). N Engl J Med 1990; 323: 1070-1071
4. Morinière P, Marie A, Esper NE et al. Destructive spondylarthropathy with β2-microglobulin deposits in a uremic patient before chronic hemodialysis. Nephron 1991; 59: 654-657
5. Gejyo F, Yamada T, Odani S et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706
6. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985; 76: 2425-2429
7. Garcia-Garcia M, Garcia-Valero J, Mourad G, Argilés A. Protein constituents of amyloid deposits in beta 2-microglobulin amyloidosis. Rev Rhum [Engl Ed] 1994; 61 (9, suppl): 7S-11S
8. Brancaccio D, Ghiggeri GM, Braidotti P et al. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. J Am Soc Nephrol 1995; 6: 1262-1270
9. Charra B, Calemard E, Uzan M, Terrat JC, Vanel T, Laurent G. Carpal tunnel syndrome, shoulder pain and amyloid deposits in long-term haemodialysis patients. Proc EDTA-ERA 1984; 21: 291-295
10. vanYpersele de Strihou C, Jadoul M, Malghem L, Maldague B, Jamart J. and the Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patients' age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012-1019
11. Bardin T, Zingraff J, Shirahama T et al. Hemodialysis associated amyloidosis and beta-2 microglobulin: a clinical and immunohistochemical study. Am J Med 1987; 83: 419-424
12. Sebert JL, Fardellone P, Deramont H et al. Spondylarthropathie destructive avec dépôts amyloïdes chez 3 patients en hémodialyse chronique. Rev Rhum 1986; 53: 459-465
13. Sanchez R, Praga M, Salas JJR et al. Compressive myelopathy due to dialysis-associated amyloidosis. Nephron 1993; 65: 463-465
14. Deforges-Lasseur C, Combe C, Cernier A, Vital JM, Aparicio M. Destructive spondylarthropathy presenting with progressive paraplegia in a dialysis patient. Recovery after surgical spinal cord decompression and parathyroidectomy. Nephrol Dial Transplant 1993; 8: 180-184
15. Zingraff J, Noël LH, Bardin T, Kuntz D, Dubost C, Drücke T. Beta-2 microglobulin amyloidosis: a sternoclavicular joint biopsy study in hemodialysis patients. Clin Nephrol 1990; 33: 94-97
16. Jadoul M, Garbar C, Rorive G, Hanique G, van Ypersele de Strihou C. Post-mortem joint β2M amyloidosis as a function of hemodialysis duration and patients' age (abstract). J Am Soc Nephrol 1994; 5: 456
17. Jadoul M, Malghem J, van de Berg B, van Ypersele de Strihou C. Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a longitudinal and cross-sectional study. Nephrol Dial Transplant 1993; 8: 1104-1109
18. Muñoz-Gomez J, Bergada-Brado E, Gomez-Perez R et al. Amyloid arthropathy in patients undergoing periodical hemodialysis for renal failure: a new complication. Ann Rheum Dis 1985; 44: 729-733
19. DiRaimondo C, Casey T, DiRaimondo C, Stone W. Pathologic fractures associated with idiopathic amyloidosis of bone in hemodialysis patients. Nephron 1986; 43: 22-27
20. Morita T, Suzuki M, Kaminura A, Hirasawa Y. Amyloidosis of a possible new type in patients receiving long term haemodiaiysis. Arch Pathol Lab Med 1985; 109: 1029-1032
21. Shirahama T, Skinner M, Cohen AS et al. Histochemical and immunohistochemical characterization of amyloid associated with chronic hemodialysis as beta-2 microglobulin. Lab Invest 1985; 53: 705-709
22. Miura Y, Ishiyama T, Inomata A et al. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis. Nephron 1992; 60: 268-273
23. Grateau G, Zingraff J, Fauchet M et al. Radionuclide exploration of dialysis amyloidosis. Preliminary experience. Am J Kidney Dis 1988; 11: 231-237
24. Nelson SR, Hawkins PN, Richardson S et al. Imaging of haemodialysis-associated amyloidosis using 123-I-serum amyloid P component. Lancet 1991; 338: 335-339
25. Floege L, Burchert W, Nonnast-Daniel B et al. Imaging of dialysis-related amyloid AB-amyloid) deposits with 1311-β2-microglobulin. Kidney Int 1990; 38: 1169-1176
26. Zingraff J, Caillat-Vigneron N, Ureña P et al. Plasma kinetics of 125-I-labelled amyloid P component in β2-M amyloidosis: a possible approach to quantitate disease activity. Nephrol Dial Transplant 1995; 10: 223-229
27. Noël L-H, Zingraff J, Bardin T, Atienza C, Kuntz D, Drüeke T. Tissue distribution of dialysis amyloidosis. Clin Nephrol 1987; 27: 175-178
28. Ogawa H, Saito A, Hirabayashi N, Hara K. Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 1987; 28: 199-204
29. Theaker JM, Raine AEG, Rainey AJ, Heryet A, Clark A, Oliver DO. Systemic amyloidosis of β-2 microglobulin type: a complication of long term haemodialysis. J Clin Pathol 1987; 40: 1247-1251
30. Ho-Soon HC, Heller D, Picken MM, Sidhu GS, Kahn T Infarction of intestine with massive amyloid deposition in two patients on long-term hemodialysis. Gastroenterology 1989; 96: 230-234
31. Gal R, Korzets A, Schwartz A, Rath-Wolfson L, Gafter U. Systemic distribution of β2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Arch Pathol Lab Med 1994; 118: 718-721
32. Zingraff J, Bardin T, Noël LH, Drüeke T. Lack of haemodialysis associated amyloidosis (letter). Lancet 1991; 338: 1089
33. Fernandez-Alonso J, Rios-Camacho C, Valenzuela-Castano A, Hernanz-Mediano W. Mixed systemic amyloidosis in a patient receiving long-term haemodialysis. J Clin Pathol 1994; 47: 560-561
34. Zingraff J, Droz D, Youam M, Voisin MC, Drüeke TB. Chronic arthropathy and rectal bleeding in a long-term hemodialysis patient. Nephrol Dial Transplant 1995; 10: 2153-2155
35. Vincent C, Revillard J, Galland R, Traeger J. Serum β2-M in hemodialyzed patients. Nephron 1978; 21: 260-268
36. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990; 87: 6353-6357
37. Haag-Weber M, Mai B, Hörl WH. Isolation of a granulocyte inhibitory protein from uraemic patients with homology of β2-microglobulin. Nephrol Dial Transplant 1994; 9: 382-388
38. Gejyo F, Odani S, Yamada T et al. β-2 microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986; 30: 385-390
39. Floege J, Granolleras C, Bingel M et al. β-2-microglobulin kinetics during hemodialysis and hemofiltration. Nephrol Dial Transplant 1987; 1: 223-229
40. Zingraff J, Beyne P, Ureña P et al. Influence of haemodialysis membranes on β2 microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284-290
41. Mrowka C, Schiffl H. Comparative evaluation of β2-microglobulin removal by different hemodialysis membranes: a sixyear follow-up. Nephron 1993; 63: 368-369
42. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293-1302
43. Odell RA, Slowiaczek P, Moran JE, Schindhelm K. Beta 2-microglobulin kinetics in end-stage renal failure. Kidney Int 1991; 39: 909-919
44. Floege J, Bartsch A, Schulze M, Shaldon S, Koch KM, Smeby LC. Clearance and synthesis rates of β2-microglobulin in patients undergoing hemodialysis and in normal subjects. J Lab Clin Med 1991; 118: 153-165
45. Vincent C, Chanard J, Caudwell V, Lavaud S, Wong T, Revillard JP. Kinetics of 125-I-β2-microglobulin turnover in dialyzed patients. Kidney Int 1992; 42: 1434-1443
46. Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on beta 2 microglobulin production and cellular expression. Kidney Int 1990; 38: 962-968
47. Schoels M, Jahn B, Hug F, Deppisch R, Ritz E, Hänsch GM. Stimulation of mononuclear cells by contact with cuprophan membranes: further increase of β2-microglobulin synthesis by activated late complement components. Am J Kidney Dis 1993; 21: 394-399
48. Cohen AS, Connors LH. The pathogenesis and biochemistry of amyloidosis. J Pathol 1987; 151: 1-10
49. Connors L, Shirahama T, Skinner M, Fenves A, Cohen AS. In vitro formation of amyloid fibrils from intact β2-microglobulin. Biochem Biophys Res Commun 1985; 131: 1063-1068
50. Campistol JM, Solé M, Bombi JA, et al. In vitro spontaneous synthesis of β2-microglobulin amyloid fibrils. Am J Pathol 1992; 141: 241-248
51. Ono K, Uchino F. Formation of amyloid-like substance from beta-2-microglobulin in vitro. Nephron 1994; 66: 404-407
52. Ohishi H, Skinner M, Sato-Araki N, Okuyama T, Gejyo F, Kimura A. Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver and spleen. Clin Chem 1990; 36: 88-91
53. Aruga E, Ozasa H, Teraoka S, Ota K. Macromolecules that are colocalized with deposits of β2-microglobulin in hemodialysis-associated amyloidosis. Lab Invest 1993; 1993: 223-230
54. Argilés A, Kerr PG, Mourad G, Mion CM, Atkins RC. Serum alpha-2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transplant 1993; 8: 1118-1123
55. Linke RP, Hampl H, Lobeck H et al. Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 1989; 36: 675-681
56. Argilés A, Garcia-Garcia M, Derancourt J, Mourad G, Demaille JG. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits. Kidney Int 1995; 48: 1397-1405
57. Campistol JM, Bernard D, Papastoitsis G, Solé M, Kasirsky J, Skinner M. Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis. Kidney Int 1996; 50: 1262-1267
58. Miyata T, Oda O, Inagi R et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1252
59. Miyata T, Inagi R, Iida Y et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93: 521-528
60. Vincent C, Dennoroy L, Revillard JP. Molecular variants of β2-microglobulin in renal insufficiency. Biochem J 1994; 298: 181-187
61. Miyata T, Iida Y, Ueda Y et al. Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end products. Kidney Int 1996; 49: 538-550
62. Miyata T, Taneda S, Ueda Y et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-2358
63. ε-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50: 1303-1309
64. Miyasaka N, Sato K, Kitano Y, Higaki M, Nishioka K, Ohta K. Aberrant cytokine production from tenosynovium in dialysis associated amyloidosis. Ann Rheum Dis 1992; 51: 797-802
65. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C et al. Advanced oxidation protein products as a novel marker of oxydative stress in uremia. Kidney Int 1996; 49: 1304-1313
66. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985; 28: 158-167
67. Capeillère-Blandin C, Delaveau T, Descamps-Latscha B. Structural modifications of human beta-2 microglobulin treated with oxygen-derived radicals. Biochem J 1991; 277: 175-182
68. Chanard J, Bindi P, Toupance O, Maheut H, Lacour F. Carpal tunnel syndrome and type of dialysis membrane. Br Med J 1989; 298: 867-868
69. Brunner FP, Brynger H, Ehrich JHH et al. Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry. Nephrol Dial Transplant 1990;
70. Kessler M, Netter P, Azoulay E, Mayeux D, Pere P. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. Br J Rhumatol 1992; 61: 157-162
71. van Ypersele de Strihou C. Influence of dialysis techniques on β2M amyloidosis. Rev Rhum (Engl Ed) 1994; 61 (9, suppl): 67S-69S
72. Cornélis F, Bardin T, Faller B et al. Rheumatic syndromes and beta 2 microglobulin amyloidosis in patients receiving long-term peritoneal dialysis. Arthritis Rheum 1989; 32: 785-788
73. Renaud H, Fournier A, Morinière P, Westeel PF, Marie A, Sebert JL. Ostéoarthropathie multifocale associée à une amylose par dépôts de beta-2-microglobuline chez un insuffisant rénal traité uniquement par hémofiltration. Néphrologie 1988; 9: 89-94
74. Baz M, Durand C, Ragon A et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681-685
75. Tan SY, Irish A, Winearls CG et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50; 282-289
76. Bardin T, Lebail-Darne JL, Zingraff J et al. Dialysis arthropathy: outcome after renal transplantation. Am J Med 1995; 99: 243-248
77. Jadoul M, Noel H, Malghem J, Galant C, van Ypersele de Strihou C. Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. Am J Kidney Dis 1996; 27: 888-890
78. Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse β2-microglobulin amyloidosis. J Am Soc Nephrol 1996; 7: 798-804
79. Moe SH, Hack BK, Cummings SA, Sprague SM. Role of IL-1β and prostaglandins in β2-microglobulin-induced bone mineral dissolution. Kidney Int 1995; 47: 587-591
80. Balint EM, Marshall C, Miyata T, Sprague SM. β2-Microglobulin induces IL-6 production from cultured neonatal mouse calvaria (abstract A1115). J Am Soc Nephrol 1996; 7: 1472
81. Centrella M, McCarthy TL, Canalis E. β2-microglobulin enhances insulin-like growth factor I receptor and synthesis in bone cell cultures. J Biol Chem 1989; 264: 18268-18271
82. Jennings JC, Mohan S, Baylink DJ. β2-Microglobulin is not a bone cell mitogen. Endocrinology 1989; 125: 404-409
83. Homma N, Gejyo F, Isemura M, Arakawa M. Collagen-binding affinity of beta2-microglobulin, a preprotein of hemodialysis-associated amyloidosis. Nephron 1989; 53: 37-40
84. Brinckerhoff CE, Mitchell TI, Karmilowicz MJ, Kluve-Beckermann B, Benson MD. Autocrine induction of collagenase by serum amyloid A-like and β2-microglobulin-like proteins. Science 1989; 243: 655-657
85. Ferreira A, Ureña P, Ang KS et al. Relationship between serum β2-microglobulin, bone histology and dialysis membranes in uraemic patients. Nephrol Dial Transplant 1995; 10: 1701-1707
86. Ripoll E, Revilla M, Hernandez ER, Arribas I, Villa LF, Rico H. New evidence that serum β2-microglobulin behaves as a biological marker of bone remodelling in women. Eur J Clin Invest 1996; 26: 681-685